Targacept to Present at CIBC and Lazard Investor Conferences
Winston-Salem, North Carolina
October 29, 2007
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences:
- The 18th Annual CIBC World Markets Healthcare Conference at the Waldorf-Astoria Hotel in New York City on Monday, November 5, 2007 at 12:45 p.m. Eastern Standard Time; and
- Lazard Capital Markets Fourth Annual Healthcare Conference at The New York Palace in New York City on Tuesday, November 27, 2007 at 1:00 p.m. Eastern Standard Time.
Each presentation will be webcast and accessible from the Investor Relations page of the Company’s website at www.targacept.com. Each webcast will also be available for replay on the Company’s website for at least two weeks following the corresponding event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled start time.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Its product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease and cognitive deficits in schizophrenia, pain, and depression and anxiety disorders, as well as multiple preclinical programs. Targacept also has strategic alliances with AstraZeneca and GlaxoSmithKline. Additional information about Targacept is available at www.targacept.com.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 419-1555
Email: linnmich@comcast.net
Back to Newsroom